Replies to post #43711 on lowtrade

[The GidDy uP Kid]

filed last year as well as news http://www.otcmarkets.com/stock/SAFC/filings

We are a development stage company that has acquired a patent-pending technology for a voice-enabled protector for administering medicine. We do not have any plans to manufacture or develop our product. Rather, we plan to license the patent-pending technology to one or more third party partners who will be responsible for designing, developing, manufacturing, and selling their product, branded with their corporate identity as they determine best fits their sales program. In exchange for this licensing agreement, the partner or partners will agree to pay to SafeCode Drug Technologies Corp. an upfront fee and royalties on an ongoing basis. http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9453715

On January 20, 2013, the Company entered into a technology transfer and sale agreement with Sindolor Medical Ltd. Pursuant to the Agreement the Company acquired all rights and title to certain products and technologies in consideration of a $110,000 convertible note.

JERUSALEM, Israel, March 12, 2013 /PRNewswire/ --

SafeCode Drug Technologies acquired Quickool and EasyJet technology from Sindolor Medical Ltd., an Israel-based medical technologies development company.

http://www.prnewswire.com/news-releases/safecode-drug-technologies-acquires-breakthrough-painless-injection-technology-197309031.html

Quote:On January 6th, 2013, Biomedix announced that they are going to fund and purchase SAFC shares at $.15 a piece. Biomedix already owns approximately $200,000 worth of this company’s shares. SAFC will also be enabling the share buyback program. This will last between 1 and 3 months. The shares will ultimately be used for issuance’s of acquisitions of companies in the medical industry. The money will be returned to the treasury of the company. Up to $1M will be accepted into this buyback program at a rate of $.20 per share.

http://bestdamnpennys4bucks.com/safc-safecode-drug-technologies-corp/

****http://clinicaltrials.gov/show/NCT00684333

JERUSALEM, April 17, 2013 /PRNewswire/ –

SafeCode Drug Technologies Corp. (SAFC), a developer of technologies that reduces errors and eliminates pain during the administration of prescription medications, announced today that the company intends to hire a Project Manager to oversee and implement a marketing strategy to commercialize its newly acquired painless injection device.

The company’s new technology is fully approved by the Federal Drug Administration (FDA), and has demonstrated itself to be safe and effective in actively reducing pain during the administration of blood tests, lanching and injections – a daily reality for many during ongoing medical care.

Both EZJect and Quickool – the newly acquired technologies – received FDA approval for commercialization in 2007.
http://microcapvoice.com/?p=1363